Literature DB >> 18618242

Treatment of sleep disordered breathing in congestive heart failure.

Samuel L Krachman1, Gilbert E D'Alonzo, Irene Permut, Wissam Chatila.   

Abstract

In patients with congestive heart failure, sleep disordered breathing occurs commonly and is associated with an increased mortality. In addition to central sleep apnea (Cheyne-Stokes respiration), obstructive sleep apnea is more prevalent in patients with congestive heart failure than in the general population. As a result, a number of treatments have been investigated, with varying results. While many therapies may improve the severity of sleep disordered breathing, only positive pressure ventilation has been shown to improve cardiac function. Newer forms of positive pressure ventilation, such as adaptive servo-ventilation, appear to be even more effective at correcting central sleep apnea. Whether any of these treatments have an effect on transplant-free survival is presently unknown and awaits further study.

Entities:  

Mesh:

Year:  2008        PMID: 18618242     DOI: 10.1007/s10741-008-9099-5

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  88 in total

1.  Inhibition of awake sympathetic nerve activity of heart failure patients with obstructive sleep apnea by nocturnal continuous positive airway pressure.

Authors:  Kengo Usui; T Douglas Bradley; Jonas Spaak; Clodagh M Ryan; Toshihiko Kubo; Yasuyuki Kaneko; John S Floras
Journal:  J Am Coll Cardiol       Date:  2005-06-21       Impact factor: 24.094

2.  Leftward shift of the interventricular septum and pulsus paradoxus in obstructive sleep apnea syndrome.

Authors:  T Shiomi; C Guilleminault; R Stoohs; I Schnittger
Journal:  Chest       Date:  1991-10       Impact factor: 9.410

3.  Continuous positive airway pressure for central sleep apnea and heart failure.

Authors:  T Douglas Bradley; Alexander G Logan; R John Kimoff; Frédéric Sériès; Debra Morrison; Kathleen Ferguson; Israel Belenkie; Michael Pfeifer; John Fleetham; Patrick Hanly; Mark Smilovitch; George Tomlinson; John S Floras
Journal:  N Engl J Med       Date:  2005-11-10       Impact factor: 91.245

4.  Prognostic value of nocturnal Cheyne-Stokes respiration in chronic heart failure.

Authors:  P A Lanfranchi; A Braghiroli; E Bosimini; G Mazzuero; R Colombo; C F Donner; P Giannuzzi
Journal:  Circulation       Date:  1999-03-23       Impact factor: 29.690

5.  Augmented sympathetic neural response to simulated obstructive apnoea in human heart failure.

Authors:  T Douglas Bradley; Ruzena Tkacova; Michael J Hall; Shin-ichi Ando; John S Floras
Journal:  Clin Sci (Lond)       Date:  2003-03       Impact factor: 6.124

6.  Sleep apnea in 81 ambulatory male patients with stable heart failure. Types and their prevalences, consequences, and presentations.

Authors:  S Javaheri; T J Parker; J D Liming; W S Corbett; H Nishiyama; L Wexler; G A Roselle
Journal:  Circulation       Date:  1998-06-02       Impact factor: 29.690

7.  Relationship of systolic BP to obstructive sleep apnea in patients with heart failure.

Authors:  Don D Sin; Fabia Fitzgerald; John D Parker; Gary E Newton; Alexander G Logan; John S Floras; T Douglas Bradley
Journal:  Chest       Date:  2003-05       Impact factor: 9.410

8.  Nocturnal oxygen and hypercapnic ventilatory response in patients with congestive heart failure.

Authors:  S Andreas; F von zur Mühlen; J Stevens; H Kreuzer
Journal:  Respir Med       Date:  1998-03       Impact factor: 3.415

9.  Enhanced ventilatory response to exercise in patients with chronic heart failure and central sleep apnea.

Authors:  Michael Arzt; Martina Harth; Andreas Luchner; Frank Muders; Stephan R Holmer; Friedrich C Blumberg; Günter A J Riegger; Michael Pfeifer
Journal:  Circulation       Date:  2003-04-14       Impact factor: 29.690

10.  Increased mortality associated with Cheyne-Stokes respiration in patients with congestive heart failure.

Authors:  P J Hanly; N S Zuberi-Khokhar
Journal:  Am J Respir Crit Care Med       Date:  1996-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.